Citius Oncology (NASDAQ:CTOR – Get Free Report) announced its earnings results on Friday. The company reported ($0.09) earnings per share for the quarter, Zacks reports.
Citius Oncology Stock Down 2.3 %
Shares of CTOR stock opened at $1.25 on Friday. The business’s 50-day moving average price is $1.17. Citius Oncology has a 12-month low of $0.85 and a 12-month high of $49.00. The company has a debt-to-equity ratio of 0.08, a current ratio of 0.34 and a quick ratio of 0.08.
Analyst Upgrades and Downgrades
Separately, Maxim Group began coverage on shares of Citius Oncology in a report on Wednesday, November 27th. They issued a “buy” rating and a $3.00 price target on the stock.
About Citius Oncology
Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.
Featured Stories
- Five stocks we like better than Citius Oncology
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Symbotic Shares Down 37%—Is It Time for Bravery or Caution?
- Pros And Cons Of Monthly Dividend Stocks
- High-Yield Healthcare: 3 Stocks With Strong Dividends
- Retail Stocks Investing, Explained
- Beyond the Bargain Bin: 3 Stocks Leading Discount Retail
Receive News & Ratings for Citius Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
